Skip to main content

Day: December 7, 2023

Saga Communications, Inc. Declares a Special Cash Dividend of $2.00 per Share

GROSSE POINTE FARMS, Mich., Dec. 07, 2023 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) (the “Company”, “Saga” or “our”) today announced that its Board of Directors (“Board”) declared a special cash dividend of $2.00 per share. The dividend will be paid on January 12, 2024, to shareholders of record on December 20, 2023. The aggregate amount of the payment to be made in connection with the special dividend will be approximately $12.5 million. The special cash dividend will be funded by cash on the Company’s balance sheet and is in line with the Board’s goal of reducing our ongoing cash and short-term investment balances to approximately $25 million prior to future cash flows being recognized. The Board continues to have discussions relative to the right level of cash to maintain on our balance sheet and this...

Continue reading

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years

December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United StatesFirst Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years COPENHAGEN, DENMARK and BOSTON, MA, December 7, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be marketed as ProNephro AKITM (NGAL). ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker test cleared for pediatric use (aged 3 months through 21 years) in the US. ProNephro AKI (NGAL) is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI within 48-72 hours in the intensive care unit (ICU) setting. Unlike serum creatinine, a muscle by-product...

Continue reading

Trupanion, leading pet medical insurance provider, teams up with renowned animal health experts to raise awareness around pet behavioral health

Trupanion-hosted event reveals 5 key tips for managing pet behavioral health SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, collaborated with a panel of world-renowned animal health experts, to host a live event, “Understanding and Managing Pet Behavioral Health”, shedding light on the growing issue of pet behavioral health and its potential impact on both our pets and ourselves. Responding to the pressing questions of Trupanion pet parents on this topic, Trupanion Chief Veterinary Officer, Dr. Steve Weinrauch, BVMS, MRCVS, facilitated the discussion by bringing together three experts in the fields of veterinary medicine: Dr. E’Lise Christensen, Diplomate American College of Veterinary Behaviorists, Dr. Kathy Murphy, BVetMed, DPhil,...

Continue reading

Global Ship Lease Announces CEO Transition

Thomas Lister to Become CEO; Ian Webber to Join Board of Directors LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company” or “GSL”), a leading independent owner of containerships, today announced that Ian Webber, its Chief Executive Officer, has chosen to retire from the CEO role he has held since the Company’s inception in 2007 and will join GSL’s Board of Directors, effective March 31, 2024, expanding the size of the Board to nine members. Thomas Lister, who also joined the Company in 2007 and has held a number of senior executive roles, has been appointed to succeed Mr. Webber as CEO, effective concurrently with Mr. Webber’s retirement. Thomas Lister was part of the management team that took GSL public in August 2008, and has served as Chief Commercial Officer of the Company since then, having...

Continue reading

Crown Castle Announces CEO Transition

Jay Brown to Retire as President and CEO; Anthony Melone Appointed Interim CEO HOUSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) — Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today announced that Jay Brown informed the Company’s Board of Directors on December 6, 2023 of his decision to retire as Crown Castle’s President, Chief Executive Officer and a Director of the Company, effective January 16, 2024. The Board has appointed Anthony Melone, a member of Crown Castle’s Board, to begin serving as interim CEO at that time. The Board will conduct a search process to identify a permanent CEO. Mr. Melone has over three decades of experience in the telecommunications industry, including having served as Executive Vice President and Chief Technology Officer (“CTO”) for Verizon Communications from December 2010 to April 2015....

Continue reading

Insight Acquisition Corp. Announces Confidential Submission of Form S-4 Registration Statement in Connection with Proposed Business Combination

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) — Insight Acquisition Corp. (“Insight” or “IAC”) (NASDAQ: INAQ), a publicly traded special purpose acquisition company, today announced the confidential submission with the U.S. Securities and Exchange Commission (“SEC”) of a draft registration statement on Form S-4 (the “Registration Statement”) in connection with the proposed business combination with Alpha Modus, Corp. based in Metro-Charlotte, NC (the “Business Combination”). About Alpha Modus Through its aggregate ‘571 patent holdings, Alpha Modus engages in creating, developing and licensing data-driven technologies to enhance consumers’ in-store digital experience at the point of decision. The company was founded in 2014 and is headquartered in Cornelius, North Carolina. For additional information, please visit alphamodus.com. About...

Continue reading

CooperCompanies Announces Fourth Quarter and Full Year 2023 Results

SAN RAMON, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2023.Fourth quarter 2023 revenue of $927.1 million, up 9%, and up 9% organically. Fiscal year 2023 revenue of $3.6 billion, up 9%, or up 10% organically. Fourth quarter 2023 GAAP diluted earnings per share (EPS) of $1.70, up 29%. Fiscal 2023 GAAP diluted EPS of $5.91, down 24%. Fourth quarter 2023 non-GAAP diluted EPS of $3.47, up 26%. Fiscal 2023 non-GAAP diluted EPS of $12.81, up 3%. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.Commenting on the results, Al White, Cooper’s President and CEO, said, “Fiscal 2023 was another year of record annual revenue driven...

Continue reading

CubeSmart Announces 4.1% Increase in Quarterly Common Dividend

MALVERN, Pa., Dec. 07, 2023 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) announced today that its Board of Trustees declared a quarterly dividend of $0.51 per common share for the period ending December 31, 2023. The dividend is payable on January 16, 2024 to common shareholders of record on January 2, 2024. The quarterly distribution represents an annualized dividend rate of $2.04 per share, an increase of $0.08 per share from the previous annual rate of $1.96 per share. “We are proud to announce the 14th consecutive annual increase to our dividend,” commented President and Chief Executive Officer Christopher P. Marr. “Our team continues to execute on our growth strategy, and we remain committed to sharing in that growth with our shareholders.” About the Company CubeSmart is a self-administered and self-managed real estate investment...

Continue reading

Genasys Inc. Reports Fiscal Fourth Quarter and Fiscal Year 2023 Financial Results

Genasys Protect Software Gaining Momentum SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the leader in Protective Communications, today announced financial results for the Company’s fiscal fourth quarter and full year ended September 30, 2023. Richard S. Danforth, Chief Executive Officer of Genasys, Inc., commented, “As we announced in mid- September, our pipeline of hardware and software business continues to grow rapidly. This week’s announcements include some of the business that we had expected in the September quarter. We expect that we will book each of the forecasted hardware orders that shifted out of our fiscal 2023. In the fourth quarter of fiscal 2023, recurring revenues in our software business were up 43% year over year and 21% sequentially. Based on current contracting activity, the addition...

Continue reading

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023

— Recorded Second Quarter Revenue of $25.4 Million — — Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million — — Entered into Partnership with California Institute of Regenerative Medicine (CIRM) to Advance Manufacturing of Adeno-Associated Adenovirus, as well as Other Cell and Gene Therapy Programs – — Completed Construction of Cell and Gene Therapy Facility; Grand Opening Scheduled for January 2024 — — Adjusting Fiscal 2024 Revenue Guidance to $137 to $147 million — TUSTIN, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.